Eli Lilly tops growth factor grades among S&P healthcare holdings
The S&P 500 has experienced a challenging two-week period marked by escalating geopolitical tensions, sector rotation...
Tag: LLY
Eli Lilly warns of safety risks from compounded obesity drugs after finding impurity
Eli Lilly (LLY) has issued a public warning about potential safety risks associated with compounded tirzepatide mixed with...
Lilly eyes $3B investment in China as it seeks approval for weight loss pill
Announcing the submission of a marketing application for its experimental weight loss drug, orforglipron, in China, Eli...
Hims & Hers hires former Lilly communications chief
Hims & Hers Health (HIMS) has made a major change in its PR function with the hiring of Kathryn Beiser, who has served...
Lilly says GLP-1 access for some Medicare members could exceed $50 monthly cap
Eli Lilly (LLY) has said that monthly out-of-pocket costs for some Medicare enrollees taking its weight loss and obesity...
Novo, Hims & Hers said to be eyeing a partnership to sell obesity drugs
Novo Nordisk (NVO) is planning to sell its obesity drugs on the telehealth platform run by Hims & Hers Health (HIMS) as...
Lilly launches program to drive employee access to obesity care
Eli Lilly (LLY) announced on Thursday the launch of the Employer Connect platform, which enables employees to access its...
Rigel Pharma slides as falling contract revenue to drive contraction
Shares of Rigel Pharmaceuticals (RIGL) reached a four-month low on Wednesday after the company, with its Q4 2025 results,...
Most and least shorted mid-to mega-cap healthcare stocks in February
The healthcare sector is facing aggressive short selling, particularly targeting high-growth disruptors while avoiding major...
Hims & Hers back in red as FDA doubles down on GLP-1 compounders
Following over a 13% gain in the prior session, Hims & Hers (HIMS) traded lower after the U.S. FDA sent a new batch of...